Page last updated: 2024-12-07
alpha-Cyclohexylmandelic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 97700 |
| CHEMBL ID | 1333063 |
| CHEBI ID | 165187 |
| SCHEMBL ID | 198082 |
Synonyms (89)
| Synonym |
|---|
| AC-16189 |
| 4335-77-7 |
| nsc28945 |
| nsc-28945 |
| benzeneacetic acid, alpha-cyclohexyl-alpha-hydroxy- |
| kl-007-m1 |
| einecs 224-380-4 |
| nsc 28945 |
| (+-)-cyclohexylphenylglycolic acid |
| rcc 32 |
| alpha-phenylcyclohexaneglycolic acid |
| alpha-cyclohexyl-alpha-hydroxybenzeneacetic acid |
| acide phenylcyclohexylhydroxyacetique [french] |
| nsc 93969 |
| hexahydrobenzilic acid |
| phenyl-cyclohexylglycolic acid |
| cyclohexaneglycolic acid, alpha-phenyl- |
| OPREA1_543150 |
| nsc93969 |
| nsc-93969 |
| CHEMDIV2_000672 |
| STK364404 |
| cyclohexyl(hydroxy)phenylacetic acid |
| cyclohexyl-hydroxy-phenyl-acetic acid |
| alpha-cyclohexylmandelic acid |
| smr000518539 |
| MLS001211653 |
| AKOS000300197 |
| 2-cyclohexyl-2-hydroxy-2-phenylacetic acid |
| CHEBI:165187 |
| HMS1370O12 |
| FT-0665346 |
| FT-0665345 |
| NCGC00245367-01 |
| cyclohexylphenylglycolic acid |
| alpha-cyclohexyl-dl-mandelic acid |
| C2393 |
| cyclohexylmandelic acid |
| acide phenylcyclohexylhydroxyacetique |
| unii-qh762w903u |
| qh762w903u , |
| CCG-106579 |
| 2-cyclohexyl-2-hydroxy-phenylacetic acid |
| cyclohexyl mandelic acid |
| a-cyclohexylmandelic acid |
| alpha cyclohexylmandelic acid |
| a-cyclohexyl-a-hydroxyphenyl acetic acid |
| 2-cyclohexyl-2-phenylglycolic acid |
| 2-cyclohexyl-2-hydroxy-2-phenyl-acetic acid |
| HMS2833F08 |
| 2-cyclohexylmandelic acid |
| FT-0635236 |
| AM20040469 |
| rcc-32 |
| benzeneacetic acid, .alpha.-cyclohexyl-.alpha.-hydroxy- |
| cpga |
| .alpha.-phenylcyclohexylglycolic acid |
| oxybutynin hydrochloride impurity d [ep impurity] |
| .alpha.-cyclohexyl-.alpha.-phenylglycolic acid |
| .alpha.-cyclohexyl-dl-mandelic acid |
| SCHEMBL198082 |
| SY011590 |
| mfcd00194543 |
| phenylcyclohexylglycolic acid |
| CHEMBL1333063 |
| AKOS016842341 |
| AE-641/03292035 |
| cyclohexylphenyl glycolic acid |
| YTRNSQPXEDGWMR-UHFFFAOYSA-N |
| cyclohexyl (hydroxy) phenyl acetic acid |
| 2-cyclohexyl-2-hydroxy-2-phenyl acetic acid |
| alpha-cyclohexylphenylglycolic acid |
| cyclohexyl-hydroxy-phenylacetic acid |
| W-106234 |
| DS-1292 |
| 50896-04-3 |
| alpha-cyclohexylmandelic acid, 97% |
| |a inverted exclamation mark-cyclohexylmandelic acid |
| (rs)-2-cyclohexyl-2-hydroxy-2-phenylacetic acid (phenylcyclohexylglycolic acid) |
| benzeneacetic acid,a-cyclohexyl-a-hydroxy- |
| BCP22302 |
| BRD-A49752073-001-07-3 |
| benzeneacetic acid, a-cyclohexyl-a-hydroxy- |
| Q27287264 |
| EN300-7392541 |
| CS-0156519 |
| DTXSID50863369 |
| 2-cyclohexyl-2-hydroxy-2-phenylaceticacid |
| Z1741965610 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| benzenes | Any benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (3)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 1.3371 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 0.1635 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 89.1251 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (14)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1215579 | Activity of human recombinant CES2 expressed in baculovirus-infected High Five insect cells assessed as enzyme-mediated compound formation formation treated with oxybutynin at 10 uM for 30 mins by HPLC analysis in presence of 10 uM CES1 inhibitor NDGA | 2012 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5 | Conclusive identification of the oxybutynin-hydrolyzing enzyme in human liver. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.35
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||